Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma

doi:10.4239/wjd.v15.i4.645

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (513)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

349

Figures (1-3)

Tables (1-3)

Sum=442

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=23

Apr 15, 2024 (publication date) through May 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Apr 15, 2024; 15(4): 645-653
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.645

Full Size Figure Download Figure

Figure 2 Comparison of serum inflammatory cytokines after chemotherapy. A: Tumor necrosis factor-α level of the two groups after chemotherapy; B: Interleukin-6 Level of the two groups after chemotherapy; C: High-sensitivity C-reactive protein level of the two groups after chemotherapy. ^bP < 0.001. TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; hs-CRP: High-sensitivity C-reactive protein.

Citation: Fang TZ, Wu XQ, Zhao TQ, Wang SS, Fu GMZ, Wu QL, Zhou CW. Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma. World J Diabetes 2024; 15(4): 645-653
URL: https://www.wjgnet.com/1948-9358/full/v15/i4/645.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i4.645